'Myeloma' diaporamas de présentation

Multiple Myeloma: Pathogenesis and Clinical Presentation

Multiple Myeloma: Pathogenesis and Clinical Presentation. Tammy Weyer PA-C. Objectives:. Discuss Pathogenenesis Review Clinical Presentation of Multiple Myeloma: Diagnostic Work-Up Criteria for diagnosis Staging Treatment Options. Multiple Myeloma.

2.08k views • 67 slides

873 views • 64 slides

MULTIPLE MYELOMA (MM)

MULTIPLE MYELOMA (MM). Curs an IV - limba engleza 2012-2013. MM - Background. Definition: B-cell malignancy characterised by abnormal proliferation of plasma cells able to produce a monoclonal immunoglobulin (M protein ). MM - Background.

861 views • 60 slides

Multiple myeloma (MM)

Multiple myeloma (MM). The second most common adult haematological malignancy. MM is a clonal malignancy of terminally differentiated plasma cells. Multiple myeloma: Epidemiology and incidence. Annual incidence of approximately 30-50 per million.

1.31k views • 59 slides

798 views • 54 slides

Epidemiology

Acute and chronic renal failure. Etiology, pathogenesis. Diagnostics. Clinical picture. Complications. Principles of treatment. The role of a doctor-dentist in early diagnostics and prophylaxis. Epidemiology

650 views • 49 slides

Scottsdale, Arizona

Scottsdale, Arizona. Rochester, Minnesota. Jacksonville, Florida. Multiple Myeloma Monitoring and Therapy. Angela Dispenzieri, M.D. IMF Patient Workshop November 3, 2014. Mayo Clinic College of Medicine Mayo Clinic Comprehensive Cancer Center. Multiple Myeloma

680 views • 42 slides

Haematological Malignancies in General Practice

Haematological Malignancies in General Practice. Judith Hanslip Consultant Haematologist Lister Hospital, Stevenage. Jon Lambert Consultant Haematologist UCLH & Mt Vernon Cancer Centre. Case 1. 21 year old woman with 3 week history of dry cough and cervical lymphadenopathy

733 views • 34 slides

Starting Therapy for Low Risk Myeloma

Starting Therapy for Low Risk Myeloma. Robert Z. Orlowski, Ph.D., M.D. Director, Myeloma Section Professor, Departments of Lymphoma/Myeloma & Experimental Therapeutics Principal Investigator, M. D. Anderson SPORE in Multiple Myeloma Chair, Southwest Oncology Group Myeloma Committee.

525 views • 34 slides

Starting Therapy for Low Risk Myeloma

Starting Therapy for Low Risk Myeloma. Robert Z. Orlowski, Ph.D., M.D. Director, Myeloma Section Professor, Departments of Lymphoma/Myeloma & Experimental Therapeutics Principal Investigator, M. D. Anderson SPORE in Multiple Myeloma Chair, Southwest Oncology Group Myeloma Committee.

461 views • 34 slides

Myeloma 101 and Standards of Care for Myeloma

Myeloma 101 and Standards of Care for Myeloma. Joanne Hewitt PhD, NP, CON(C) Nurse Practitioner Cross Cancer Institute October 13, 2018 MASS Education Conference. What Is Multiple Myeloma?. Cancer of the plasma cells in bone marrow Growth of myeloma cells:

920 views • 31 slides

Fifty Years of Progress and the Future of Myeloma

Fifty Years of Progress and the Future of Myeloma. Myeloma Research Roundtable Scottsdale, Arizona March 21, 2014 Robert A. Kyle, MD. Scottsdale, Arizona. Rochester, Minnesota. Jacksonville, Florida. CP1123175-1. Disclosures for Robert A. Kyle. None Related to this presentation.

472 views • 30 slides

Integrative whole transcriptome sequencing in myeloma and MCL therapy

Integrative whole transcriptome sequencing in myeloma and MCL therapy. Selina Chen-Kiang Professor Weill Cornell Medical College October 24 , 2013. Disclosures: None. Positive. Go. p16 p15 p18 p19. Cyclin D + CDK4/6. mid-G1 checkpoint. pS-Rb-E2F. p21 p27 p57.

362 views • 29 slides

Le discrasie plasmacellulari

Le discrasie plasmacellulari. Discrasie plasmacellulari I: Gammopatia monoclonale di significato indeterminato (MGUS): primitiva secondaria Mieloma Multiplo Smoldering myeloma Plasma cell leukemia Mieloma micromolecolare Mieloma non-secernente

684 views • 27 slides

Multiple Myeloma: Is it now a curable disease?

Multiple Myeloma: Is it now a curable disease?. Pritesh Patel, MD. OVErview. Disease overview How I approach initial treatment Treatment considerations at relapse. How many people are affected by myeloma?. ?96,000 MM patients.

404 views • 26 slides

I&I ESA Stem

I&I ESA Stem. Immunology only. What is innate immunity Non-specific immediate immune response to antigens What are the components of innate immunity Physical Skin Secretions Mucus Normal bacterial flora Cellular Macrophages Neutrophils Eosinophils Basophils and mast cells

401 views • 25 slides

Supportive Care in Multiple Myeloma

Supportive Care in Multiple Myeloma. Natalie S. Callander, M.D Clinical Myeloma Program. Objectives: review health issues particularly important in living with myeloma. Neutropenia/Anemia Bone health Peripheral neuropathy Pain management Supplements. Normal CBC values.

416 views • 23 slides

Multiple Myeloma

Multiple Myeloma. Plasma cell malignancy About 300 new cases in Norway each year Incurable Mean survival after diagnosis: 3-4 years Malignant plasma cells found in the bone marrow Osteolytic lesions common complication. Chromosomal-translocations associated with human cancer.

619 views • 18 slides

Introduction to Myeloma: Diagnosis, Treatment, Risk Factors and Prevalence

Alan Bryce, MD Staff Oncologist, Mayo Clinic Arizona. Introduction to Myeloma: Diagnosis, Treatment, Risk Factors and Prevalence. Scottsdale, Arizona. Rochester, Minnesota. Jacksonville, Florida. Multiple Myeloma - Background. The Bone Marrow (blood factory) makes 3 kinds of cells:

272 views • 16 slides

373 views • 15 slides